Amundi Asset Management US’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | $50.3M | Sell |
505,605
-3,952
| -0.8% | -$397K | 0.04% | 416 |
|
|
2020
Q4 | $50.9M | Sell |
509,557
-128,671
| -20% | -$13.6M | 0.04% | 389 |
|
|
2020
Q3 | $69.9M | Sell |
638,228
-49,684
| -7% | -$5.53M | 0.07% | 267 |
|
|
2020
Q2 | $72.8M | Sell |
687,912
-31,739
| -4% | -$3.28M | 0.09% | 239 |
|
|
2020
Q1 | $64.3M | Buy |
719,651
+1,760
| +0.2% | +$166K | 0.11% | 176 |
|
|
2019
Q4 | $71.6M | Buy |
717,891
+57,101
| +9% | +$5.38M | 0.08% | 238 |
|
|
2019
Q3 | $58.9M | Sell |
660,790
-50,405
| -7% | -$4.37M | 0.09% | 243 |
|
|
2019
Q2 | $58.7M | Buy |
711,195
+66,835
| +10% | +$5.24M | 0.05% | 280 |
|
|
2019
Q1 | $52.1M | Buy |
644,360
+100,822
| +19% | +$7.95M | 0.07% | 272 |
|
|
2018
Q4 | $41.3K | Buy |
543,538
+1,620
| +0.3% | +$127K | 0.04% | 293 |
|
|
2018
Q3 | $42.9M | Buy |
541,918
+748
| +0.1% | +$56.6K | 0.06% | 321 |
|
|
2018
Q2 | $38M | Sell |
541,170
-41,689
| -7% | -$3M | 0.05% | 338 |
|
|
2018
Q1 | $40.8M | Sell |
582,859
-2,351
| -0.4% | -$163K | 0.07% | 300 |
|
|
2017
Q4 | $40.6M | Sell |
585,210
-12,170
| -2% | -$821K | 0.06% | 298 |
|
|
2017
Q3 | $40.5M | Sell |
597,380
-2,405
| -0.4% | -$152K | 0.13% | 130 |
|
|
2017
Q2 | $40.9M | Buy |
599,785
+6,883
| +1% | +$449K | 0.13% | 130 |
|
|
2017
Q1 | $36.9M | Sell |
592,902
-4,300
| -0.7% | -$250K | 0.12% | 136 |
|
|
2016
Q4 | $32.6M | Buy |
597,202
+373,831
| +167% | +$21.2M | 0.11% | 150 |
|
|
2016
Q3 | $14.7M | Sell |
223,371
-242
| -0.1% | -$15.8K | 0.05% | 255 |
|
|
2016
Q2 | $13.5M | Buy |
223,613
+356
| +0.2% | +$20.7K | 0.05% | 257 |
|
|
2016
Q1 | $12.6M | Sell |
223,257
-877,588
| -80% | -$52.7M | 0.05% | 265 |
|
|
2015
Q4 | $74.7M | Buy |
1,100,845
+339,507
| +45% | +$22.3M | 0.28% | 96 |
|
|
2015
Q3 | $48.5M | Buy |
761,338
+2,279
| +0.3% | +$150K | 0.2% | 128 |
|
|
2015
Q2 | $48.4M | Buy |
759,059
+561
| +0.1% | +$38.4K | 0.18% | 152 |
|
|
2015
Q1 | $51.9M | Buy |
758,498
+4,171
| +0.6% | +$290K | 0.19% | 138 |
|
|
2014
Q4 | $53.1M | Buy |
754,327
+527,106
| +232% | +$37.7M | 0.19% | 140 |
|
|
2014
Q3 | $16.2M | Buy |
227,221
+1,417
| +0.6% | +$104K | 0.06% | 278 |
|
|
2014
Q2 | $16.8M | Sell |
225,804
-233,494
| -51% | -$16.9M | 0.06% | 278 |
|
|
2014
Q1 | $29.8M | Sell |
459,298
-192,541
| -30% | -$12.4M | 0.11% | 197 |
|
|
2013
Q4 | $38.7M | Buy |
651,839
+61,717
| +10% | +$3.35M | 0.15% | 172 |
|
|
2013
Q3 | $30.6M | Buy |
590,122
+113,061
| +24% | +$5.68M | 0.12% | 190 |
|
|
2013
Q2 | $22.6M | Buy |
+477,061
| New | +$24.3M | 0.09% | 240 |
|
Other funds holding AZN
Amundi Asset Management US's AZN Position: Q1 2021 in Review
Amundi Asset Management US reduced its AstraZeneca (AZN) stake by 0.78% in Q1 2021, selling an estimated $397K and leaving 505,605 shares worth $50.3M. The position accounts for 0.04% of the portfolio, ranked #416.
Amundi Asset Management US first reported a position in AZN in Q2 2013 and has held it in 32 quarters since. The position peaked at $74.7M in Q4 2015. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.
- Amundi Asset Management US held 505,605 shares of AstraZeneca worth $50.3M as of Q1 2021.
- Amundi Asset Management US sold 3,952 AstraZeneca shares in Q1 2021, an estimated $397K.
- AstraZeneca made up 0.04% of Amundi Asset Management US's portfolio in Q1 2021, its #416 holding.
- Amundi Asset Management US first reported a position in AstraZeneca in Q2 2013 and has held it in 32 quarters since.
- Amundi Asset Management US's AstraZeneca position peaked at $74.7M in Q4 2015.
- 756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.
Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.